Multiple Myeloma | Specialty

EU Approval of Ixazomib for Relapsed/Refractory Myeloma

April 28th 2017

Defining Progression in Multiple Myeloma

April 28th 2017

Early versus Late Response in Multiple Myeloma

April 28th 2017

Maintenance Therapy in Multiple Myeloma

April 28th 2017

Transplant Timing in Multiple Myeloma

April 28th 2017

Upfront Therapy for Myeloma; Impact on Choice at Relapse

April 28th 2017

The Ever-Changing Landscape of Myeloma Therapy

April 28th 2017

Dr. Kumar on Recent Advancements in the Field of Multiple Myeloma

April 27th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses some of the recent advancements, including FDA approvals, in the field of multiple myeloma.

Kite Unveils Novel BCMA-Directed CAR T-cell Therapy

April 21st 2017

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Dr. Usmani on Combining Daratumumab for Multiple Myeloma

April 20th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Consolidation Approach Extends PFS in Multiple Myeloma

April 20th 2017

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

Guideline Emphasizes Emotional, Physical Needs of Myeloma Patients

April 18th 2017

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

April 12th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

Beyond Myeloma: New Roles for IMiDs

April 10th 2017

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.

FDA Approval Sought for Denosumab in Myeloma

April 6th 2017

A supplemental biologics license application has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma.

Dr. Landgren on Managing Toxicities of Multiple Myeloma Treatment

April 3rd 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

Dr. Smith Discusses CAR T Cells in Multiple Myeloma

March 28th 2017

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

March 24th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma

March 24th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.